Introduction
The Prostate Imaging and Data Reporting System version 2 (PI-RADS v2) aims to simplify performance, interpretation, and reporting of prostate magnetic resonance imaging (MRI).
1 PI-RADS v2 introduced probability scores (assessment categories, Table 1 ), which indicate the likelihood of clinically significant cancer (Gleason score ≥7) 2 based upon MRI findings. PI-RADS v2 has been validated as accurate for detection of cancers and improves interobserver agreement. 3 Despite this, in our experience, use of PI-RADS v2 scores in practice is variable. This study evaluated a method to improve use of PI-RADS v2 scores by using a plan-dostudy-act (PDSA) analysis.
Methods
This retrospective, single-institution study was conducted under a waiver from the institutional review board. Our PDSA cycle included: 1) a "plan" to improve use of PI-RADS v2 scores; 2) "doing" through education (lectures on PI-RADS v2 given by the Director of Prostate Imaging [Nicola Schieda]; and distributed literature highlighting PI-RADS v2) and providing a standardized reporting template with "pick-list" fields for PI-RADS v2 scores; 3) "studying" use; and 4) "acting" through feedback on use and urologist satisfaction with reporting. 
Time periods

Statistical analysis
Comparisons were performed using the Chi-square test and ANOVA. Statistical analysis was performed using STATA v13 (Statcorp).
Results
Distribution of patients was: 35.6% (110/309) pre-intervention, 37.2% (115/309) intervention, and 27.2% (84/309) post-intervention. Mean patient age was 64.1±8.9 years with no difference across time periods (p=0.39). 
Discussion
In this study, a simple intervention improved the use of prostate MRI reporting templates and PI-RADS v2 scoring. An association between reduced time from positive MRI and subsequent TB likely indicates enhanced communication between urologists and radiologists. The simple strategy of Moran et al a standardized prostate MRI report, which includes "picklist" options for PI-RADS v2 scores, could be implemented in most radiology departments. The success of this study is multifaceted. The first relates to ease of use of the new system, allowing radiologists to use a predetermined "pick-list" for PI-RADS v2 scores. Second may be how the radiologists in this study viewed structured reporting positively, overall (templates are commonly used at our institution) and after re-enforcement through feedback from urologists. Hawkins et al 4 demonstrated radiologists preferred structured reports after an internal review. Similarly, Stilseth et al 5 showed that urologists prefer fully structured prostate MRI reporting, whereas radiologists prefer hybrid reporting. Radiologist preference may be a potential roadblock towards universal adoption of structured reporting; however, through education and feedback, this could be improved. Rosenkrantz et al 6 showed the benefit of long-term followup after intervention to maintain adherence to providing a summary score on prostate MRI.
Radiologists in our study seldom provided PI-RADS v2 scores for negative studies, exposing a potential lack of understanding regarding use of PI-RADS v2. Stilseth et al 5 showed that among surveyed radiologists and urologists, roughly half thought PI-RADS v2 was not applied correctly by radiologists. Impediments to use were speculated to be due to urologist/radiologist inexperience and lack of standardized template reporting. Larson et al 7 found consensusbuilding efforts to be critical in development and implementation of structured reports, and that department-wide structured reporting can be implemented in such a way that radiologists prefer to use the standard reports.
PI-RADS v2 and the present study aim to enhance communication between radiologists and urologists through the use of probability scores. Our study indicates that PI-RADS v2 scores improve communication, with a significant decrease in time between positive MRI and TB without any other differences in patient access to account for the observation. In our study, roughly 40% of positive MRIs had no immediate TB, likely related to high number of AS patients in our cohort and inclusion of PI-RADS v2 score 3 lesions, where biopsy could be delayed to coincide with AS protocols when there is stability in other clinical factors. Barentsz et al 8 stress that PI-RADS v2 scores must be incorporated with clinical factors when determining need and strategy for biopsy.
Conclusion
Our study demonstrates that through education, the use structured reporting templates, "pick-list" options for PI-RADS v2 assessment categories, and through user feedback and support from urologists, the use of PI-RADS v2 can be improved in clinical practice.
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